Study S001310

A Multicenter, Randomized, Double-blind, Placebo- Parallel Controlled, Phase III Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise Alone

ClinicalTrials.gov record

Registration

Registration: NCT06650007
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 218
Start: 2024-11-08
Primary completion: 2026-01-21
Lead sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:HRS9531 Injection; DRUG:HRS9531 Placebo Injection
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Change in HbA1c [from baseline to 36 weeks treatment]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.